HT-1 drug study in china withdrawn before starting
NCT ID NCT06227429
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to observe how patients with hereditary tyrosinemia type 1 (HT-1) in China respond to nitisinone treatment in everyday medical practice. It planned to track serious health events like liver problems or death. However, the study was withdrawn before enrolling any participants, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nitisinone (Orfadin)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY TYROSINEMIA, TYPE I are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Swedish Orphan Biovitrum Research Site
Beijing, China
-
Swedish Orphan Biovitrum Research Site
Chongqing, China
-
Swedish Orphan Biovitrum Research Site
Hefei, China
-
Swedish Orphan Biovitrum Research Site
Wuhan, China